Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
by Mary Stuart
As the song by Bob Dylan says, "You can't win with a losing hand." Dealt by R&D with a toxic...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Series B cash will be used to advance its Stargardt disease gene therapy.
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.
Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.
Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.
